Asthma-related deaths
| First author [ref.] | Daily dose of randomised treatment | Concomitant LABA therapy | ICS-exposed patient | Cause of death |
| Pauwels 26 | Formoterol 4.5 μg p.r.n. | Salmeterol | Yes | Asthma |
| Pauwels 26 | Formoterol 4.5 μg p.r.n. | Yes | Asthma | |
| Pauwels 26 | Formoterol 4.5 μg p.r.n. | No | Asthma | |
| O'Byrne 28 | Formoterol/budesonide 9/160 μg plus terbutaline 400 μg p.r.n. | Yes | Asthma | |
| O'Byrne 29 | Formoterol 9 μg plus budesonide 160 μg | Yes | Status asthmaticus | |
| Pleskow 32 | Formoterol 48 μg | No | Asthma | |
| von Berg 33 | Formoterol 18 μg | Yes | Respiratory failure | |
| Pauwels 26 | Salbutamol 200 μg p.r.n. | No | Asthma | |
| Pauwels 26 | Salbutamol 200 μg p.r.n. | Yes | Asthma |
LABA: long-acting β-agonist; ICS: inhaled corticosteroids.